Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06066255 | PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM | PHASE2 | NOT YET_RECRUITING | 27 | — | — | Mar 31, 2024 | Mar 31, 2026 | Feb 20, 2024 | - | — |
To assess the rate of grade 2-4 acute GVHD post allograft using the MAGIC classification.
| Name | Type | Description |
|---|---|---|
| Thymoglobulin Injectable Product | DRUG | single intravenous injection of thymoglobulin |
Inclusion Criteria: * Adults aged ≥ 60 or aged 50 to 59 with comorbidities (HCT-CI10 score ≥ 3), * Hematological malignancies except myeloproliferative syndrome and myelodysplastic syndrome, * Patient having received an allograft within ≤ 35 days, performed with the following modalities: * First...